Allogeneic Stem Cell Transplantation for Patients with Relapsed Chemorefractory Aggressive Non-Hodgkin Lymphomas-Reference-Cited by-同舟云学术

Allogeneic Stem Cell Transplantation for Patients with Relapsed Chemorefractory Aggressive Non-Hodgkin Lymphomas

Published:2009-05 Issue:5 Volume:15 Page:547-553
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Hamadani Mehdi,Benson Don M.,Hofmeister Craig C.,Elder Patrick,Blum William,Porcu Pierluigi,Garzon Ramiro,Blum Kristie A.,Lin Thomas S.,Marcucci Guido,Devine Steven M.

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference28 articles.

1. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma;Philip;N Engl J Med,1987

2. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma;Philip;N Engl J Med,1995

3. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma;Verdonck;N Engl J Med,1995

4. Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience;Chen;Biol Blood Marrow Transplant,2008

5. Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma;Chen;Br J Haematol,2001

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The place of allogeneic stem cell transplantation in aggressive B-cell non-Hodgkin lymphoma in the era of CAR-T-cell therapy;Frontiers in Medicine;2022-12-06

2. Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics;Blood Advances;2022-02-02

3. Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis;Blood Advances;2022-01-18

4. Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies;Blood;2019-04-18

5. Outcomes of myeloablative peripheral blood stem cell transplantation for non-complete remission patients with relapsed/refractory peripheral T cell lymphomas;Annals of Hematology;2018-12-11